Loading...

Quinlan Sievers, MD, PhD

Title(s)Resident Physician, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard Medical School, Boston, MAMD/PhD2019Cancer Biology
    Lab of Cathy Wu, MD, DFCI, Boston, MALab technician2011Tumor immunology, therapeutic vaccination
    Williams College, Williamstown, MABA2009Biology/Studio Art

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Slabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 Jul 11; 134(2):160-170. PMID: 31043423.
      View in: PubMed
    2. Sievers QL, Petzold G, Bunker RD, Renneville A, Slabicki M, Liddicoat BJ, Abdulrahman W, Mikkelsen T, Ebert BL, Thomä NH. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018 11 02; 362(6414). PMID: 30385546.
      View in: PubMed
    3. Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood. 2018 09 20; 132(12):1293-1303. PMID: 30042095.
      View in: PubMed